Annals of Hematology

, Volume 98, Issue 2, pp 457–464 | Cite as

Validation of the Marginal Zone Lymphoma International Prognostic Index

  • Joohyun Hong
  • Junhun Cho
  • Young Hye Ko
  • Seok Jin Kim
  • Won Seog KimEmail author
Original Article


The Marginal Zone Lymphoma International Prognostic Index (MALT-IPI) was recently developed for use in patients with mucosa-associated lymphoid tissue (MALT) lymphoma based on age, serum lactate dehydrogenase level, and Ann Arbor stage. In this study, we aimed to validate the MALT-IPI. A total of 455 MALT lymphoma patients were included in this study from between January 2005 and February 2017. Event-free survival (EFS), progression-free survival (PFS), cause-specific survival (CSS), and overall survival (OS) were the primary outcomes. Of the 455 patients, MALT-IPI low-, intermediate-, and high-risk groups included 309 (67.9%), 126 (27.7%), and 20 (4.4%) individuals, respectively. When comparing the low-risk group (L MALT-IPI) with the intermediate–high-risk group (I-H MALT-IPI), EFS, PFS, CSS, and OS were significantly different (p = 0.000, p = 0.000, p = 0.027, and p = 0.037). The International Prognostic Index and the Follicular Lymphoma International Prognostic Index failed to predict the prognosis of MALT lymphoma. Use of the MALT-IPI significantly differentiated L MALT-IPI from I-H MALT-IPI with respect to EFS, PFS, CSS, and OS. MALT-IPI is a valuable tool for the prediction of MALT lymphoma prognosis.


MALT-IPI MALT lymphoma 


Compliance with ethical standards

This study was approved by the institutional review board (IRB) of Samsung Medical Center in Seoul, Korea (IRB number 2018-02-076).

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Kahl B, Yang D (2008) Marginal zone lymphomas: management of nodal, splenic, and MALT NHL. Hematology Am Soc Hematol Educ Program 89:359–364Google Scholar
  2. 2.
    Anderson J, Armitage JO, Berger F, Cavalli F, Chan WC, Close J, Coiffier B, Connors J, Diebold J, Gascoyne R, Harris N, Hiddemann W, Ho FCS, Jacobs P, Liang RHS, Lister TA, MacLennan K, Muller-Hermelink HK, Nathwani BN, Norton A, Ott G, Pedrinis E, Roy P, Schauer A, Weisenburger DD (1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood 89:3909–3918Google Scholar
  3. 3.
    Al-Hamadani M, Habermann TM, Cerhan JR, Macon WR, Maurer MJ, Go RS (2015) Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011. Am J Hematol 90:790–795CrossRefGoogle Scholar
  4. 4.
    Zinzani PL (2012) The many faces of marginal zone lymphoma. Hematology Am Soc Hematol Educ Program 2012:426–432Google Scholar
  5. 5.
    International Non-Hodgkin’s Lymphoma Prognostic Factors P (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329:987–994CrossRefGoogle Scholar
  6. 6.
    Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, Au WY, Bellei M, Brice P, Caballero D, Coiffier B, Conde-Garcia E, Doyen C, Federico M, Fisher RI, Garcia-Conde JF, Guglielmi C, Hagenbeek A, Haioun C, LeBlanc M, Lister AT, Lopez-Guillermo A, McLaughlin P, Milpied N, Morel P, Mounier N, Proctor SJ, Rohatiner A, Smith P, Soubeyran P, Tilly H, Vitolo U, Zinzani PL, Zucca E, Montserrat E (2004) Follicular lymphoma international prognostic index. Blood 104:1258–1265CrossRefGoogle Scholar
  7. 7.
    Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, Pro B, Pileri S, Pulsoni A, Soubeyran P, Cortelazzo S, Martinelli G, Martelli M, Rigacci L, Arcaini L, Di Raimondo F, Merli F, Sabattini E, McLaughlin P, Solal-Celigny P (2009) Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 27:4555–4562CrossRefGoogle Scholar
  8. 8.
    Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, Pfreundschuh M, Reiser M, Metzner B, Einsele H, Peter N, Jung W, Wormann B, Ludwig WD, Duhrsen U, Eimermacher H, Wandt H, Hasford J, Hiddemann W, Unterhalt M, German Low Grade Lymphoma Study G, European Mantle Cell Lymphoma N (2008) A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111:558–565CrossRefGoogle Scholar
  9. 9.
    Thieblemont C, Cascione L, Conconi A, Kiesewetter B, Raderer M, Gaidano G, Martelli M, Laszlo D, Coiffier B, Lopez Guillermo A, Torri V, Cavalli F, Johnson PW, Zucca E (2017) A MALT lymphoma prognostic index. Blood 130:1409–1417CrossRefGoogle Scholar
  10. 10.
    Bacon CM, Du MQ, Dogan A (2007) Mucosa-associated lymphoid tissue (MALT) lymphoma: a practical guide for pathologists. J Clin Pathol 60:361–372CrossRefGoogle Scholar
  11. 11.
    Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V, International Harmonization Project on L (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579–586CrossRefGoogle Scholar
  12. 12.
    Raderer M, Vorbeck F, Formanek M, Osterreicher C, Valencak J, Penz M, Kornek G, Hamilton G, Dragosics B, Chott A (2000) Importance of extensive staging in patients with mucosa-associated lymphoid tissue (MALT)-type lymphoma. Br J Cancer 83:454–457CrossRefGoogle Scholar
  13. 13.
    Ueda K, Terui Y, Yokoyama M, Sakajiri S, Nishimura N, Tsuyama N, Takeuchi K, Hatake K (2013) Non-gastric advanced mucosa-associated lymphoid tissue (MALT) lymphoma has worse prognosis than gastric MALT lymphoma even when treated with rituximab-containing chemotherapy. Leuk Lymphoma 54:1928–1933CrossRefGoogle Scholar
  14. 14.
    Raderer M, Streubel B, Woehrer S, Puespoek A, Jaeger U, Formanek M, Chott A (2005) High relapse rate in patients with MALT lymphoma warrants lifelong follow-up. Clin Cancer Res 11:3349–3352CrossRefGoogle Scholar
  15. 15.
    Cohen SM, Petryk M, Varma M, Kozuch PS, Ames ED, Grossbard ML (2006) Non-Hodgkin’s lymphoma of mucosa-associated lymphoid tissue. Oncologist 11:1100–1117CrossRefGoogle Scholar
  16. 16.
    Troch M, Wohrer S, Raderer M (2010) Assessment of the prognostic indices IPI and FLIPI in patients with mucosa-associated lymphoid tissue lymphoma. Anticancer Res 30:635–639Google Scholar
  17. 17.
    Starr AG, Caimi PF, Fu P, Massoud MR, Meyerson H, Hsi ED, Mansur DB, Cherian S, Singh AD, Cooper BW, De Lima MJ, Lazarus HM, Gerson SL, Jagadeesh D, Smith MR, Dean RM, Pohlman BL, Hill BT, William BM (2016) Dual institution experience of extranodal marginal zone lymphoma reveals excellent long-term outcomes. Br J Haematol 173:404–412CrossRefGoogle Scholar
  18. 18.
    Oh SY, Ryoo BY, Kim WS, Park YH, Kim K, Kim HJ, Kwon JM, Lee J, Ko YH, Ahn YC, Oh SJ, Lee SI, Kim HJ, Kwon HC, Bang SM, Kim JH, Park J, Lee SS, Kim HY, Park K (2007) Nongastric marginal zone B-cell lymphoma: analysis of 247 cases. Am J Hematol 82:446–452CrossRefGoogle Scholar
  19. 19.
    Arcaini L, Burcheri S, Rossi A, Passamonti F, Paulli M, Boveri E, Brusamolino E, Orlandi E, Molteni A, Pulsoni A, Cox MC, Orsucci L, Fabbri A, Frezzato M, Voso MT, Zaja F, Montanari F, Pascutto C, Morra E, Cortelazzo S, Lazzarino M (2006) Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination. Oncologist 11:285–291CrossRefGoogle Scholar
  20. 20.
    Heilgeist A, McClanahan F, Ho AD, Witzens-Harig M (2013) Prognostic value of the Follicular Lymphoma International Prognostic Index score in marginal zone lymphoma: an analysis of clinical presentation and outcome in 144 patients. Cancer 119:99–106CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Joohyun Hong
    • 1
  • Junhun Cho
    • 2
  • Young Hye Ko
    • 2
  • Seok Jin Kim
    • 1
  • Won Seog Kim
    • 1
    Email author
  1. 1.Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, School of MedicineSungkyunkwan UniversityeSeoulSouth Korea
  2. 2.Department of Pathology, Samsung Medical Center, School of MedicineSungkyunkwan UniversitySeoulSouth Korea

Personalised recommendations